CytomX Therapeutics Up 9%; AbbVie Picks Second Target Under Collaboration

Date : 07/09/2019 @ 4:55PM
Source : Dow Jones News
Stock : AbbVie Inc (ABBV)
Quote : 73.37  -1.76 (-2.34%) @ 1:00AM
After Hours
Last Trade
Last $ 73.04 ▼ -0.33 (-0.45%)

CytomX Therapeutics Up 9%; AbbVie Picks Second Target Under Collaboration

CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart

1 Year : From Apr 2019 to Apr 2020

Click Here for more CytomX Therapeutics Charts.

By Michael Dabaie


CytomX Therapeutics Inc. (CTMX) shares were up 9% to $12.03 in heavier-than-average volume Tuesday.

The clinical-stage oncology-focused biopharmaceutical company said its partner AbbVie (ABBV) selected a second target under the companies' 2016 agreement to discover and develop Probody drug conjugates.

The target selection triggers a $10 million payment to CytomX from AbbVie. The companies are also advancing clinical-stage asset CX-2029 under a global co-development and licensing agreement, CytomX said.


Write to Michael Dabaie at


(END) Dow Jones Newswires

July 09, 2019 11:40 ET (15:40 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest ABBV Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.